Virus infection and direct-acting antivirals in pregnancy
Clinical and Experimental Obstetrics and Gynecology
; 49(4), 2022.
Article
in English
| EMBASE | ID: covidwho-1822730
ABSTRACT
Objective:
Antiviral therapy during pregnancy has always presented difficulties in clinical practice. This review covers the safety and efficacy of the direct use of antivirals during pregnancy. Mechanism We conducted literature research to summarize the available evidence on the use of direct-acting antivirals during pregnancy for infections due to influenza, hepatitis B and C, human immunodeficiency, herpes simplex virus, cytomegalovirus, varicella-zoster virus, Ebola, and Zika viruses, and human coronavirus. Findings in brief To support further the rational use of antivirals during pregnancy, the discussion includes the influence of pregnancy on pharmacokinetics, safety, and transplacental permeability, and the protection of mothers and children from vertical transmission.Conclusion:
Data on the use of antiviral drugs during pregnancy are currently insufficient. Promoting research on the ethics of drug experimentation, and pharmacokinetics, drug metabolism, and pharmacological effects of pregnancy, is essential to improve the care of pregnant women and even save lives during current and future outbreaks.
adult; child; complication; Coronavirinae; Cytomegalovirus; drug effect; drug metabolism; drug safety; Ebola hemorrhagic fever; ethics; female; hepatitis B; Herpes simplex virus; human; immune deficiency; influenza; mother to child transmission; nonhuman; pharmacokinetics; pregnancy; pregnancy complication; pregnant woman; review; Varicella zoster virus; vertical transmission; Zika virus; antivirus agent
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
English
Journal:
Clinical and Experimental Obstetrics and Gynecology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS